Synthesis and characterization of substituted benzoylhydrazones of naloxone

Synapse

Volumn 24, Issue 2, 1996, Pages 193-201

  Ciszewska, Grazyna R ^a   Ginos, James A ^a   Charton, Marvin ^c   Standifer, Kelly M ^a   Brooks, Andrew I ^a   Brown, George P ^a   Ryan Moro, Jennifer P ^a   Berzetei Gurske, Ilona ^d   Toll, Lawrence ^d   Pasternak, Gavril W ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c PRATT INSTITUTE   (United States)

^d SRI INTERNATIONAL   (United States)

Author keywords

Kappa3 Receptor; Morphine; Opiate; Opioid Receptor; Structure Activity Relationships

Indexed keywords

DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALOXONE BENZOYLHYDRAZONE; OPIATE RECEPTOR; RECEPTOR SUBTYPE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOASSAY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GUINEA PIG; ILEUM; MALE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

EID: 0005455532     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2396(199610)24:2<193::aid-syn11>3.0.co;2-%23     Document Type: Article

References (32)

1. Berzetei-Gurske, I.P., White, A., Polgar, W., DeCosta, B.R., Pasternak, G.W., and Toll, L. (1995) The in vitro pharmacological characterization of naloxone benzoylhydrazone. Eur. J. Pharmacol., 277: 257-263.
2. 3 opioid receptors with a selective monoclonal antibody. Synapse, 22:247-252.
3. 3, subtype. J. Pharmacol. Exp. Ther., 251:461-468.
4. Charton, M. (1983) The upsilon parameter: Definition and determination. Top. Curr. Chem., 114:57-91.
5. Charton, M. (1987) A general treatment of electrical effects. Prog. Phys. Org. Chem., 16:287-315.
6. Charton, M. (1990) The quantitative description of properties and bioactivities of amino acids, peptides and proteins. Prog. Phys. Org. Chem., 18:163-284.
7. Charton, M. (1992) The quantitative description of steric effects. Stud. Org. Chem., 42:629-687.
8. 1 binding assay. Mol. Pharmacol., 34:308-317.
9. Franke, R. (1984) Theoretical Drug Design Methods. Akademie-Verlab, Berlin.
10. Gistrak, M.A., Paul, D., Hahn, E.F., and Pasternak, G.W. (1989) Pharmacological actions of a novel mixed opiate agonist/antagonist: Naloxone benzoylhydrazone. J. Pharmacol. Exp. Ther., 251:469-476.
11. Hahn, E.F., Itzhak, Y., Nishimura, S., Johnson, N., and Pasternak G.W. (1985) Irreversible opiate agonists and antagonist: III. Phenylhydrazone derivatives of naloxone and oxymorphone. J. Pharmacol. Exp. Ther., 235:846-850.
12. Hansch, C. and Leo, A. (1995) Exploring QSAR. Fundamentals and Applications in Chemistry and Biology. American Chemical Society, Washington, DC.
13. Houde, R.W. and Wallenstein, S.L. (1956) Clinical studies of morphinenalorphine combinations. Fed. Proc., 15:440-441.
14. Hughes, J., Kosterlitz, H.W., and Leslie, F.M. (1975) Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics. Br. J. Pharmacol., 53:371-381.
15. Kosterlitz, H.W. and Watt, A.J. (1968) Kinetic parameters of narcotic agonists and antagonists with particular reference to N-allylnoroxymorphone (naloxone). Br. J. Pharmacol. Chemother., 33:266-276.
16. Lasagne, L. and Beecher, H.K. (1954) The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. J. Pharmacol. Exp. Ther., 112:356-363.
17. Lord, J.A.H., Waterfield, A.A., Hughes, J., and Kosterlitz, H.W. (1977) Endogenous opioid peptides: Multiple agonists and receptors. Nature, 267:495-499.
18. Luke, M.C., Hahn, E.F., Price, M., and Pasternak, G.W. (1988) Irreversible opiate agonists and antagonists. V. Hydrazone and acylhydrazone derivatives of naltrexone. Life Sci., 43:1249-1256.
19. Martin, W.R. (1967) Opioid antagonists. Pharmacol. Rev., 19: 463-521.
20. Martin, W.R., Eades, C.G., Thompson, J.A., Huppler, R.E., and Gilbert, P.E. (1975) The effects of morphine and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther., 197:517-532.
21. 3-related opioid receptor. Mol. Pharmacol., 47:1180-1188.
22. Pasternak, G.W. (1993) Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol., 16:1-18.
23. Pasternak, G.W. and Standifer, K.M. (1995) Mapping of opioid receptors using antisense oligodeoxynucleotides: Correlating their molecular biology and pharmacology. Trends Pharmacol. Sci., 16:344-350.
24. Paul, D., Levison, J.A., Howard, D.H., Pick, C.G., Hahn, E.F., and Pasternak, G.W. (1990) Naloxone benzoylhydrazone (NalBzoH) analgesia. J. Pharmacol. Exp. Ther., 255:769-774.
25. Paul, D., Pick, C.G., Tive, L.A., and Pasternak, G.W. (1991) Pharmacological characterization of Nalorphine, a κ analgesic. J. Pharmacol. Exp. Ther., 257:1-7.
26. 3H-naloxone benzoylhydrazone: A reversible κ and slowly dissociable μ opiate. Mol. Pharmacol., 35:67-74.
27. Reseine, T. and Bell, G.I. (1994) Molecular biology of opioid receptors. Trends Neurosci., 16:506-510.
28. Ronai, A.Z., Graf, L., Szekely, J.I., Dunai-Kovacs, A.X., and Bajusz, S. (1977) Differential behavior of LPH-(61-91)-peptide in different model systems: Comparison of the opioid activities of LPH-(61-91)peptide and its fragments. FEBS Lett., 74:182-184.
29. 3 opioid receptors expressed in BE(2)-C neuroblastoma cells. J. Pharmacol. Exp. Ther., 270:1246-1255.
30. Uhl, G.R., Childers, S.R., and Pasternak, G.W. (1994) An opiate receptor gene family reunion. Trends Neurosci., 17:89-93.
31. 2 in guinea pig brain and guinea pig ileum membranes. Eur. J. Pharmacol., 231:251-258.
32. 2 opioid receptors. Proc. Natl. Acad. Sci. USA, 85:4061-4065.